01—Abstract
Summary
Summary of the 8-K filed May 1, 2024. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories reported first-quarter 2024 revenue of $964 milliona, up 7% both as reported and organically, with EPS of $2.81, up 10% as reported and 9% on a comparable basis.
Growth was led by Companion Animal Group (CAG) revenue up 7%b, with CAG Diagnostics recurring revenue also up 7%. Water revenue rose 11%, while Livestock, Poultry and Dairy (LPD) declined 3%. Gross margin expanded 120 basis points to 61.5%, but operating margin slipped 10 basis points to 31.0% because the prior-year quarter benefited from a customer contract resolution payment (about 180 basis points of headwind).
Operating expenses rose 12%, driven by higher R&D tied to the innovation agenda. Installed base of global premium instruments grew 11%, a key indicator of future recurring consumables revenue. Management updated 2024 revenue guidance to $3,895c-$3,965 million (6.5%-8.5% reported growth, 7%-9% organic), lowering the high end of organic growth by about 1 point to reflect moderating U.S. clinical visit trends.
The guidance also absorbs a roughly $35 milliond negative impact from a stronger U.S. dollar. EPS guidance was trimmed to $10.82-$11.20 from $10.84-$11.33 at the midpoint, a reduction of about $0.08, mainly from roughly $0.11 of FX headwind. Operating margin guidance of 30.2%-30.7% was maintained.
Investors will likely focus on whether the softer U.S. clinical visit trend persists and on the durability of the premium instrument placement growth that underpins recurring revenue. Cash generation remained solid: operating cash flow was $198.6 million and free cash flow was $168.3 million in the quarter.
The company repurchased about $155 million of stock in the open market and spent $77 million on an acquisition of a software and data platform business. Cash fell to $397 million at quarter-end, and the balance sheet shows a $250 million line of credit drawn and roughly $696 million in long-term debt including the current portion.
02—Key points
Key Highlights
- Q1 2024 revenue of $964.1 million grew 7% as reported and organically; CAG Diagnostics recurring revenue grew 7%, and Water grew 11%, while LPD declined 3%.
- Diluted EPS of $2.81 rose 10% as reported and 9% on a comparable basis, including $0.10 of share-based compensation tax benefits.
- Gross margin expanded 120 bps to 61.5%, while operating margin fell 10 bps to 31.0% due to lapping a prior-year customer contract resolution payment (~180 bps impact) and 12% operating expense growth.
- Global premium instrument installed base grew 11%, supporting future recurring consumables revenue (VetLab consumables up 9%).
- 2024 revenue guidance was narrowed to $3,895-$3,965 million (6.5%-8.5% reported, 7%-9% organic), with the high end of organic growth lowered by about 1 point on moderating U.S. clinical visit trends and a ~$35 million FX headwind.
- 2024 EPS guidance was lowered to $10.82-$11.20 from $10.84-$11.33 (about $0.08 at midpoint), mainly from roughly $0.11 of FX impact; operating margin guidance of 30.2%-30.7% was maintained.
- Q1 cash flow was strong at $168.3 million of free cash flow, with $155 million of open-market share repurchases and a $77 million acquisition of a software and data platform business.
03—Questions
Frequently Asked Questions
Why did IDEXX's operating margin decline if gross margin improved?
Gross margin rose 120 bps to 61.5% on business mix, lower instrument costs and better software service margins. However, operating margin fell 10 bps to 31.0% because operating expenses grew 12%, driven by higher R&D for new platform development and general and administrative costs. The prior-year quarter also included a customer contract resolution payment, which created an approximately 180 bps comparison headwind.
Why did management lower the top end of its organic revenue growth guidance?
Management reduced the high end of the organic revenue growth range by 1 point to reflect near-term moderation in U.S. clinical visit growth trends. Q1 U.S. CAG Diagnostics growth was still about 900 bps ahead of U.S. same-store clinical visit growth, but management is factoring in a slower visit environment for the rest of 2024.
How much of the EPS guidance change is from currency versus operations?
The EPS midpoint fell about $0.08, of which roughly $0.11 reflects negative foreign exchange impact from the stronger U.S. dollar. This was partly offset by lower projected net interest expense (about $21 million versus $27 million previously) and higher expected share-based compensation tax benefits (about $0.12 versus $0.10). Operating margin guidance was unchanged.
What does the 11% growth in the premium instrument installed base mean for investors?
Premium instruments are the platforms that generate recurring consumables and diagnostic revenue over their life. Double-digit installed base growth, driven by 8% global premium instrument placement growth and high customer retention, supports the sustainability of IDEXX's recurring revenue model. Investors typically view this as a leading indicator of future VetLab consumables and reference lab revenue.
Is IDEXX's capital allocation and balance sheet position a concern?
Not materially. Free cash flow of $168 million covered the $155 million of open-market buybacks and the $77 million acquisition, though cash declined to $397 million. The company's total debt, including a $250 million drawn line of credit and about $696 million of long-term debt, remains manageable relative to its cash generation. Full-year free cash flow guidance of 90%-95% of net income was reaffirmed.
04—Continue